Low Molecular Weight PEG Drug Conjugates for Solubility and Activity Balance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current polyethylene glycol (PEG) modification technology for small molecule drugs often reduces in vitro activity while increasing hydrophilicity, which can lead to reduced blood-brain barrier permeability and increased side effects, necessitating a solution to maintain or improve drug activity and bioavailability.
Innovation Solution
A polyethylene glycol-modified drug conjugate is formed by combining low molecular weight polyethylene glycol with two or more drug molecules, creating a double-group or multi-group structure that enhances hydrophilicity, flexibility, and reduces blood-brain barrier permeability, allowing for improved in vivo distribution and bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If polyethylene glycol modification is applied to small molecule drugs, then hydrophilicity and water-solubility are improved, but in vitro activity substantially reduces
Solution Approach 1:
The patent segments the PEG modification approach by using low molecular weight PEG (n=0-10) instead of high molecular weight PEG, and by controlling the degree of substitution (mono-, di-, or tri-substitution) to balance solubility improvement with activity preservation. This segmentation allows selective modification that achieves the desired solubility enhancement while minimizing activity loss.
Solution Approach 2:
The patent systematically varies key parameters including PEG chain length (n=0-10), substitution position (positions 1, 2, or 3), and substitution degree (mono-, di-, tri-) to optimize the balance between water-solubility and in vitro activity. This parameter optimization approach identifies specific PEG-modified compounds that maintain therapeutic activity while achieving improved solubility profiles.
2Object-affected harmful factors
If polyethylene glycol modification is applied to small molecule drugs, then blood-brain barrier permeability is reduced, but this may increase side effects and reduce efficacy
Solution Approach 1:
The patent optimizes PEG chain length (n=0-10) and substitution patterns to achieve the desired reduction in blood-brain barrier permeability while preserving systemic efficacy. By carefully controlling these parameters, the modification reduces CNS side effects for drugs where appropriate, while maintaining therapeutic activity at the target site.
3Duration of action of moving object
If polyethylene glycol modification is applied to small molecule drugs, then cyclic half-life is prolonged, but in vitro activity substantially reduces
Solution Approach 1:
The use of low molecular weight PEG segments (n=0-10) provides sufficient pharmacokinetic benefits including prolonged half-life and reduced clearance, while minimizing the adverse effect on in vitro activity that occurs with higher molecular weight PEG modifications. This segmented approach achieves the desired pharmacokinetic improvement with minimal activity loss.
Solution Approach 2:
The patent optimizes PEG chain length and substitution patterns to achieve the desired prolongation of cyclic half-life while minimizing activity loss. By systematically varying these parameters, the invention identifies optimal modification conditions that extend drug circulation time while preserving therapeutic activity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The PEG-modified drug conjugate exhibits increased solubility, altered oil-water distribution coefficients, reduced blood-brain barrier permeability, and enhanced in vivo activity, effectively addressing the limitations of existing PEG modification technologies.
Implementation Method 1
introducing low molecular weight polyethylene glycol into the compound structure to increase its hydrophilicity
Implementation Method 2
altered oil-water distribution coefficients
Data Source
AI summary
Provided are polyethylene glycol drug conjugates of general formula (I), (II) or (III) and pharmaceutical compositions and a use thereof. The conjugates are formed by combining low molecular weight polyethylene glycol with 2-4 drug molecules. The conjugates can interact with receptor dimers or polymers, thereby improving the in vivo distribution of the drug, changing the oil and water distribution coefficient, enhancing the pharmacological activity, reducing the blood-brain barrier permeability of the drug, and improving the bioavailability of the drug.